2-(3-氟-4-硝基苯基)乙酸甲酯 | 169339-41-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(3-氟-4-硝基苯基)乙酸甲酯
• 英文名称: methyl 2-(3-fluoro-4-nitrophenyl)acetate
• CAS: 169339-41-7
• 化学式: C₉H₈FNO₄
• 分子量: 213.165
• InChiKey: RUUXLCCTIXFRER-UHFFFAOYSA-N

物化性质

• 沸点：
  315.5±27.0 °C(Predicted)
• 密度：
  1.346±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H320,H335
• 储存条件：
  存储条件：2-8°C，干燥。

反应信息

• 作为反应物：
  描述：

  2-(3-氟-4-硝基苯基)乙酸甲酯 在 盐酸 作用下， 以90%的产率得到3-氟-4-硝基苯乙酸
  参考文献：
  名称：

  A Convergent Synthesis of 14-Membered F-O-G Ring Analogs of the Teicoplanin Binding Pocket via Intramolecular SNAr Reaction

  摘要：

  An intramolecular SNAr reaction for efficient macrocyclization via biaryl ether formation was developed for syntheses of the 14-membered macrocycles 2 and 3 related to F-O-G ring of teicoplanin 1. Chloride as well as fluoride could be used as the leaving group in this reaction. However, the latter was preferred since it required milder conditions. Both ortho and para nitro, fluoro disubstituted aromatic rings were suitable for the macrocyclization reaction with tethered aryl oxides. The nonproteinogenic alpha-amino acid 23, required for the synthesis of 3, was prepared via an asymmetric Strecker synthesis using (R)-phenylglycinol as a chiral auxiliary. The overall synthetic strategy was convergent, and the cyclization could be performed in the presence of the highly sensitive arylglycine unit without racemization.

  DOI：

  10.1021/jo00125a026
• 作为产物：
  描述：

  甲基3-氟苯酚乙酯 在 硫酸 、 硝酸 作用下， 以 水 为溶剂， 反应 2.0h， 以76%的产率得到2-(3-氟-4-硝基苯基)乙酸甲酯
  参考文献：
  名称：

  Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions

  摘要：

  与公式I对应的化合物：作为辣椒素受体配体的化合物，含有这种化合物的药物组合物，生产这种化合物的过程，以及利用它们治疗或抑制疼痛和/或其他多种疾病或症状的用途。

  公开号：

  US20080275044A1

文献信息

• Pyrimidine derivatives
  申请人：Naganuma Kenji

  公开号：US20060293343A1

  公开（公告）日：2006-12-28

  The object of the invention is to provide a novel compound having an inhibitory action on PDE4 activity with fewer side effects. The invention provides a compound represented by the following general formula (1), possible stereoisomers thereof or racemates thereof, pharmacologically acceptable salts thereof, hydrates thereof, solvated compounds thereof, or prodrugs thereof,

  本发明的目的是提供一种对PDE4活性具有抑制作用且副作用较少的新型化合物。 该发明提供了一种由以下一般式（1）表示的化合物，其可能的立体异构体或外消旋体，其药理学上可接受的盐，水合物，溶剂化合物，或前药。
• [EN] 4-(METHYL SULFONYL AMINO) PHENYL ANALOGUES AS VANILLOID ANTAGONIST SHOWING EXCELLENT ANALGESIC ACTIVITY AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME<br/>[FR] ANALOGUES DE 4-(METHYL SULFONYL AMINO)PHENYLE UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR VANILLOIDE AYANT UNE EXCELLENTE ACTIVITE ANALGESIQUE, ET COMPOSITIONS PHARMACEUTIQUE LES COMPRENANT
  申请人：DIGITALBIOTECH CO LTD

  公开号：WO2005003084A1

  公开（公告）日：2005-01-13

  The present invention relates to novel 4-(methylsulfonylamino) phenyl analogue as a potent vanilloid receptor antagonist and the pharmaceutical compositions comprising the same. The inventive compound can be useful for analgesics to prevent, alleviate or treat pain diseases or inflammatory disease comprising pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease and urgent urinary incontinence.

  本发明涉及一种新型的4-(甲磺胺基)苯基类似物，作为有效的辣椒素受体拮抗剂，以及包含该类似物的药物组合物。这种创新化合物可用于镇痛药，用于预防、缓解或治疗疼痛疾病或包括疼痛的炎症性疾病，如急性疼痛、慢性疼痛、神经痛、术后疼痛、偏头痛、关节痛、神经病、神经损伤、糖尿病性神经病、神经退行性疾病、神经性皮肤疾病、中风、膀胱过敏、肠易激综合征、哮喘或慢性阻塞性肺疾病等呼吸道疾病、皮肤、眼睛或粘膜的刺激、发热、胃十二指肠溃疡、炎症性肠病、炎症性疾病和急性尿失禁。
• 细胞周期蛋白依赖性激酶抑制剂及其应用
  申请人：南京圣和药物研发有限公司

  公开号：CN108276382B

  公开（公告）日：2022-10-18

  本发明属于医药化学领域，涉及一类作为细胞周期蛋白依赖性激酶抑制剂(CDKs)的化合物及其应用，具体地，本发明提供式I所示的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药，它们的制备方法以及含有这些化合物的药物组合物和这些化合物或组合物用于治疗癌症、组织增生类疾病或者炎性疾病的用途。本发明的化合物对CDK7具有良好的抑制活性，非常有希望成为癌症、组织增生类疾病及炎性疾病的治疗剂。
• Chemical compounds
  申请人：AstraZeneca AB

  公开号：US06441012B1

  公开（公告）日：2002-08-27

  Compound of formula (I) wherein: A is a bicyclic heteroaryl, optionally substituted with one or more substituents; B is linker group connecting group A to group D and comprising a 3 or 4 atom linker where each atom is independently selected from carbon, oxygen, nitrogen and sulphur and is optionally subsituted with one or more C1-6 alkyl groups or two of such adjacent alkyl substituents may form a ring; C is aryl or a mono or bicyclic heteroaryl, each of which can be optionally substituted; D is an aryl or heteroaryl, both of which are optionally substituted R1 is hydrogen, C1-5 alkyl, C1-3 alkanoyl or C1-3 alkoxycarbonyl; R2 to R5 are each independently selected from hydrogen, C1-6 alkyl, aryl and heteroaryl containing up to 2 heteroatoms chosen from oxygen, sulphur and nitrogen, the aryl and heteroaryl optionally substituted with C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-4 alkoxy, C1-4 alkanoyl, C1-6 alkylamino, C1-4alkylC1-6alkyoxyl, C1-6alkylaminoC1-6alkyl, nitro, cyano, halogeno, trifluoromethyl, hydroxy, (CH2)pOH where p is 1 or 2, —CO2Ra, and —CONRaRb, where Ra and Rb are independently selected from hydrogen and C1-6 alkyl or two of R2 to R5 can be taken together to form a 3 to 7 membered ring; R6 is an acidic functional group; r and s are each independently 0 or 1 with the proviso that r and s cannot both be 0; or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof.

  化合物的结构式（I），其中： A是一个双环杂芳基，可选地带有一个或多个取代基； B是连接A基团和D基团的连接基团，包括一个3或4原子连接基团，其中每个原子可独立地选择碳、氧、氮和硫，并可选地带有一个或多个C1-6烷基基团，或两个相邻的烷基取代基团可以形成一个环； C是芳基或单环或双环杂芳基，每个基团都可以选择性地被取代； D是芳基或杂芳基，两者都可以选择性地被取代； R1是氢、C1-5烷基、C1-3脂肪酰基或C1-3烷氧羰基； R2到R5每个都独立地选择自氢、C1-6烷基、含有1或2个来自氧、硫和氮的杂原子的芳基和杂芳基，其中芳基和杂芳基可选地被C1-6烷基、C2-6烯基、C2-6炔基、C1-4烷氧基、C1-4脂肪酰基、C1-6烷基氨基、C1-4烷基C1-6烷氧基、C1-6烷基氨基C1-6烷基、硝基、氰基、卤素、三氟甲基、羟基、（CH2）pOH，其中p为1或2，—CO2Ra和—CONRaRb取代，其中Ra和Rb独立地选择自氢和C1-6烷基，或者R2到R5中的两个可以结合形成一个3到7个成员的环； R6是一个酸性功能基团； r和s每个都独立地为0或1，但r和s不能同时为0；或其药学上可接受的盐或体内水解衍生物。
• 4-(Methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same
  申请人：Lee Woo Jee

  公开号：US20060258884A1

  公开（公告）日：2006-11-16

  4-(methylsulfonylamino)phenyl analogues as potent vanilloid receptor antagonists and pharmaceutical compositions comprising the same. The compounds are useful as analgesics to prevent, alleviate or treat pain diseases or inflammatory disease including pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease and urgent urinary incontinence.

  4-(甲基磺酰氨基)苯类似物作为有效的vanilloid受体拮抗剂和包含它们的制药组合物。这些化合物可用作镇痛剂，以预防、缓解或治疗疼痛疾病或炎症性疾病，包括疼痛、急性疼痛、慢性疼痛、神经病性疼痛、术后疼痛、偏头痛、关节痛、神经病、神经损伤、糖尿病神经病变、神经退行性疾病、神经性皮肤疾病、中风、膀胱过敏、肠易激综合征、呼吸系统疾病，如哮喘或慢性阻塞性肺病、皮肤、眼睛或黏膜刺激、发热、胃十二指肠溃疡、炎症性肠病、炎症性疾病和紧急的尿失禁。